Movement Alert｜Natera Intraday Rise 3.05%, Breast Cancer Phase 3 Trial Launch Drives Gains
Market Focus
Oct 06
On October 6, Natera rose 3.05% in Regular Trading, trading at $423.16 per share.
Natera's intraday strength followed the announcement of a Phase 3 trial evaluating Signatera-based treatment escalation strategies for early breast cancer. The collaboration with Alliance Foundation Trials aims to enroll 2,000 ER-positive/HER2-negative patients worldwide, combining Genentech's oral estrogen receptor degrader giredestrant with Signatera's ctDNA monitoring to guide CDK4/6 inhibitor therapy decisions. This marks Natera's significant expansion beyond its recent colorectal cancer approval in Japan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.